Share ownership Genmab A/S Nasdaq

GMAB

US3723032062

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-15 EDT			5-day change	1st Jan Change
29.08 ^USD	+1.22%		-1.56%	-5.58%

12:49am	Nordic stocks in North America, Autoliv fell 1.6 percent	FW
07-15	Genmab's Darzalex Generates $4.21 Billion in Q2 Net Trade Sales	MT

Share class: Genmab A/S

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	62,353,252	59,493,589 ( 95.41 %)	2,859,663 ( 4.586 %)	95.41 %

Major shareholders: Genmab A/S

Name	Stocks	%	Valuation
Orbis Investment Management Ltd. 2.073 %	12,925,578	2.073 %	355 M $
AllianceBernstein LP 1.533 %	9,557,149	1.533 %	263 M $
Paradigm BioCapital Advisors LP 1.278 %	7,967,836	1.278 %	219 M $
Arrowstreet Capital LP 0.7979 %	4,975,324	0.7979 %	137 M $
Renaissance Technologies LLC 0.708 %	4,414,550	0.708 %	121 M $
Aperio Group LLC 0.6924 %	4,317,361	0.6924 %	119 M $
Deep Track Capital LP 0.5875 %	3,663,250	0.5875 %	101 M $
Harding Loevner LP 0.5183 %	3,231,601	0.5183 %	89 M $
Deerfield Management Co. LP (Private Equity) 0.3948 %	2,462,000	0.3948 %	68 M $
First Trust Advisors LP 0.3947 %	2,461,342	0.3947 %	68 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Stocks	%	Valuation
Orbis Investment Management Ltd. 5.693 %	3,549,674	5.693 %	975 M $
GENMAB A/S 4.437 %	2,766,533	4.437 %	760 M $
Jan van de Winkel 1.057 %	658,932	1.057 %	181 M $
AllianceBernstein Investments Taiwan Ltd. 0.7348 %	458,160	0.7348 %	126 M $
Robert W. Baird & Co., Inc. (Equity) 0.4639 %	289,270	0.4639 %	79 M $
Nykredit Bank A/S (Investment Management) 0.4217 %	262,962	0.4217 %	72 M $
ÖKOWORLD LUX SA 0.2245 %	140,000	0.2245 %	38 M $
Carmignac UK Ltd. 0.1995 %	124,369	0.1995 %	34 M $
Sjunde AP-fonden 0.166 %	103,520	0.166 %	28 M $
Svenska Handelsbanken AB (Denmark) 0.096 %	59,870	0.096 %	16 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	134.37%
Others	8.66%
Genmab A/S	4.44%
Individuals	1.12%
SEI Investments Co.	0.15%
Fifth Third Bancorp	0.08%
Regions Financial Corp.	0.02%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	107.13%
Bermuda	26.42%
Denmark	5.02%
Switzerland	2.21%
United Kingdom	1.81%
France	1.23%
Individuals	1.12%
Canada	1.03%
Taiwan	0.73%
Norway	0.38%
Ireland	0.32%
Luxembourg	0.3%
Germany	0.25%
Sweden	0.17%
Italy	0.12%
Finland	0.1%
Australia	0.07%
Cayman Islands	0.07%
Japan	0.06%
Belgium	0.05%
Austria	0.05%
Spain	0.05%
Singapore	0.04%
Portugal	0.02%
China	0.02%
Netherlands	0.02%
South Africa	0.01%
Mexico	0.01%
New Zealand	0.01%
Hong Kong	0.01%
Liechtenstein	0.01%

Based on 1000 largest holdings

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).

Employees

3,088

Sector

Biotechnology & Medical Research

Calendar

08-05 - Earnings release - Q2 2026

More about the company